BMC Cancer 2009, 9:397 http://www.biomedcentral.com/1471-2407/9/397 9. Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J: Molecu- lar cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S- transferase Pi gene variants. Evidence for differential cata- lytic activity of the encoded proteins. J Biol Chem 1997, 272:10004-10012. 10. Sundberg K, Johansson AS, Stenberg G, Widersten M, Seidel A, Man- nervik B, et al.: Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1-1 towards carcino- genic diol epoxides of polycyclic aromatic hydrocarbons. Car- cinogenesis 1998, 19:433-436. 11. Ntais C, Polycarpou A, Ioannidis JP: Association of GSTM1, GSTT1, and GSTP1 gene polymorphisms with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2005, 14:176-181. 12. Mo Z, Gao Y, Cao Y, Gao F, Jian L: An updating meta-analysis of the GSTM1, GSTT1, and GSTP1 polymorphisms and pros- tate cancer: a HuGE review. Prostate 2009, 69:662-688. 13. Coughlin SS, Hall IJ: A review of genetic polymorphisms and prostate cancer risk. Ann Epidemiol 2002, 12:182-196. 14. Lee E, Huang Y, Zhao B, Seow-Choen F, Balakrishnan A, Chan SH: Genetic polymorphism of conjugating enzymes and cancer risk: GSTM1, GSTT1, NAT1 and NAT2. J Toxicol Sci 1998, 23(Suppl 2):140-142. 15. Sreelekha TT, Ramadas K, Pandey M, Thomas G, Nalinakumari KR, Pillai MR: Genetic polymorphism of CYP1A1, GSTM1 and GSTT1 genes in Indian oral cancer. Oral Oncol 2001, 37:593-598. 16. Katoh T, Inatomi H, Kim H, Yang M, Matsumoto T, Kawamoto T: Effects of glutathione S-transferase (GST) M1 and GSTT1 genotypes on urothelial cancer risk. Cancer Lett 1998, 132:147-152. 17. Salagovic J, Kalina I, Stubna J, Habalova V, Hrivnak M, Valansky L, et al.: Genetic polymorphism of glutathione S-transferases M1 and T1 as a risk factor in lung and bladder cancers. Neoplasma 1998, 45:312-317. 18. Nakazato H, Suzuki K, Matsui H, Koike H, Okugi H, Ohtake N, et al.: Association of genetic polymorphisms of glutathione-S- transferase genes (GSTM1, GSTT1 and GSTP1) with familial prostate cancer risk in a Japanese population. Anticancer Res 2003, 23:2897-2902. 19. Murata M, Watanabe M, Yamanaka M, Kubota Y, Ito H, Nagao M, et al.: Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett 2001, 165:171-177. 20. Steinhoff C, Franke KH, Golka K, Thier R, Romer HC, Rotzel C, et al.: Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma. Arch Toxicol 2000, 74:521-526. 21. Komiya Y, Tsukino H, Nakao H, Kuroda Y, Imai H, Katoh T: Human glutathione S-transferase A1, T1, M1, and P1 polymor- phisms and susceptibility to prostate cancer in the Japanese population. J Cancer Res Clin Oncol 2005, 131:238-242. 22. Autrup JL, Thomassen LH, Olsen JH, Wolf H, Autrup H: Glutath- ione S-transferases as risk factors in prostate cancer. Eur J Cancer Prev 1999, 8:525-532. 23. Wadelius M, Autrup JL, Stubbins MJ, Andersson SO, Johansson JE, Wadelius C, et al.: Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. Pharmacogenetics 1999, 9:333-340. 24. Gsur A, Haidinger G, Hinteregger S, Bernhofer G, Schatzl G, Mad- ersbacher S, et al.: Polymorphisms of glutathione-S-transferase genes (GSTP1, GSTM1 and GSTT1) and prostate-cancer risk. Int J Cancer 2001, 95:152-155. 25. Beer TM, Evans AJ, Hough KM, Lowe BA, McWilliams JE, Henner WD: Polymorphisms of GSTP1 and related genes and pros- tate cancer risk. Prostate Cancer Prostatic Dis 2002, 5:22-27. 26. Mallick S, Romana M, Blanchet P, Multigner L: GSTM1 and GSTT1 polymorphisms and the risk of prostate cancer in a Carib- bean population of African descent. Urology 2007, 69:1165-1169. 27. Nock NL, Liu X, Cicek MS, Li L, Macarie F, Rybicki BA, et al.: Poly- morphisms in polycyclic aromatic hydrocarbon metabolism and conjugation genes, interactions with smoking and pros- tate cancer risk. Cancer Epidemiol Biomarkers Prev 2006, 15:756-761. 28. Giri VN, Egleston B, Ruth K, Uzzo RG, Chen DY, Buyyounouski M, et al.: Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men. Cancer Prev Res (Phila Pa) 2009, 2:244-250. 29. Brasch-Andersen C, Christiansen L, Tan Q, Haagerup A, Vestbo J, Kruse TA: Possible gene dosage effect of glutathione-S-trans- ferases on atopic asthma: using real-time PCR for quantifica- tion of GSTM1 and GSTT1 gene copy numbers. Hum Mutat 2004, 24:208-214. 30. Packer BR, Yeager M, Burdett L, Welch R, Beerman M, Qi L, et al.: SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic varia- tion in candidate genes. Nucleic Acids Res 2006, 34:D617-D621. 31. Covault J, Abreu C, Kranzler H, Oncken C: Quantitative real-time PCR for gene dosage determinations in microdeletion geno- types. Biotechniques 2003, 35:594-6. 598 32. Tian C, Hinds DA, Shigeta R, Kittles R, Ballinger DG, Seldin MF: A genomewide single-nucleotide-polymorphism panel with high ancestry information for African American admixture mapping. Am J Hum Genet 2006, 79:640-649. 33. Hahn LW, Ritchie MD, Moore JH: Multifactor dimensionality reduction software for detecting gene-gene and gene-envi- ronment interactions. Bioinformatics 2003, 19:376-382. 34. Ritchie MD, Hahn LW, Moore JH: Power of multifactor dimen- sionality reduction for detecting gene-gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity. Genet Epidemiol 2003, 24:150-157. 35. Hahn LW, Moore JH: Ideal discrimination of discrete clinical endpoints using multilocus genotypes. In Silico Biol 2004, 4:183-194. 36. Jakulin A, Bratko I: Analyzing attribute depedencies. Edited by: Lavrac N, Gamberger D, Blockeel H, Todorovski L. Cavtat, Croatia.: Springer-Verlag, PKDD; 2003:229-240. 37. Demosar J, Zupan B: Orange: From Experimental Machine Learning to Interactive Data Mining, White Paper 2004. 38. Andrew AS, Nelson HH, Kelsey KT, Moore JH, Meng AC, Casella DP, et al.: Concordance of multiple analytical approaches demon- strates a complex relationship between DNA repair gene SNPs, smoking, and bladder cancer susceptibility. Carcinogen- esis 2006, 27:1030-1037. 39. Jakulin A, Bratko I, Smrike D, Demsar J, Zupan B: Attribute inter- actions in medical data analysis. Protarus: Cyprus 2003:229-238. 40. National Center for Biotechnology Information (NCBI) website 2007 [http://www.ncbi.nlm.nih.gov]. 41. Nock NL, Liu X, Cicek MS, Li L, Macarie F, Rybicki BA, et al.: Poly- morphisms in polycyclic aromatic hydrocarbon metabolism and conjugation genes, interactions with smoking and pros- tate cancer risk. Cancer Epidemiol Biomarkers Prev 2006, 15:756-761. 42. Sikka SC: Role of oxidative stress response elements and anti- oxidants in prostate cancer pathobiology and chemopreven- tion--a mechanistic approach. Curr Med Chem 2003, 10:2679-2692. 43. Kelada SN, Kardia SL, Walker AH, Wein AJ, Malkowicz SB, Rebbeck TR: The glutathione S-transferase-mu and -theta genotypes in the etiology of prostate cancer: genotype-environment interactions with smoking. Cancer Epidemiol Biomarkers Prev 2000, 9:1329-1334. 44. Fleshner NE, Klotz LH: Diet, androgens, oxidative stress and prostate cancer susceptibility. Cancer Metastasis Rev 1998, 17:325-330. 45. Abate-Shen C, Shen MM: Molecular genetics of prostate cancer. Genes Dev 2000, 14:2410-2434. 46. Choi JY, Neuhouser ML, Barnett M, Hudson M, Kristal AR, Thorn- quist M, et al.: Polymorphisms in oxidative stress-related genes are not associated with prostate cancer risk in heavy smok- ers. Cancer Epidemiol Biomarkers Prev 2007, 16:1115-1120. 47. Waris G, Ahsan H: Reactive oxygen species: role in the devel- opment of cancer and various chronic conditions. J Carcinog 2006, 5:14. 48. Miyake H, Hara I, Kamidono S, Eto H: Oxidative DNA damage in patients with prostate cancer and its response to treatment. J Urol 2004, 171:1533-1536. 49. Medeiros R, Vasconcelos A, Costa S, Pinto D, Ferreira P, Lobo F, et al.: Metabolic susceptibility genes and prostate cancer risk in Page 9 of 10 (page number not for citation purposes)